New York – November 10, 2026 -- Deerfield Management has designated Amazon Web Services (AWS) a preferred AI provider for the firm and selected portfolio companies, extending generative AI and cloud access across a healthcare investor with more than 190 professionals.
AWS technology flows into Deerfield's R&D and intelligence units
Deerfield Intelligence and Deerfield Discovery and Development (3DC) will receive AWS AI and cloud technology plus technical support. The aim is to scale proprietary healthcare AI products and spread AI capabilities across interested portfolio companies. The collaboration also targets integration of AWS AI services into Deerfield's own research, evaluation and operating processes.
The tie-up combines AWS generative AI and cloud services with Deerfield Intelligence's AI engineers and the innovation ecosystem of affiliate Cure. The stated goal is to let selected portfolio companies deploy agentic AI systems across drug discovery, operational automation and care delivery.
Selected portfolio companies get training on model scaling and inference
Beyond technology access, selected portfolio companies will receive technical enablement and training on large-scale model training, inference optimization and healthcare-specific managed services. Dan Sheeran, AWS Vice President and General Manager of Healthcare and Life Sciences, named Amazon Bio Discovery and Amazon Bedrock AgentCore as services available to interested companies. AgentCore is used to build AI agents.
Ascertain already runs agentic clinical workflows on AWS
Deerfield-backed Ascertain uses AWS services in its agentic AI platform, which automates clinical and administrative workflows such as case management and prior authorization. Mark Michalski, M.D., Deerfield's Chief Information Officer and Ascertain's CEO, said AWS's healthcare-specific services should help the company scale those capabilities.
Joint programming planned at Cure campus in New York City
Deerfield and AWS plan to co-host joint programming at Cure, the healthcare innovation campus in New York City that houses Deerfield's headquarters. Deerfield's team includes more than 60 MDs, JDs and PhDs. Managing Partner Jim Flynn said the Intelligence team is developing models to change how the firm sources opportunities, evaluates science and accelerates portfolio companies.